Full video transcriptClick to expand
Auto-generated transcript of @chezziemai's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So here is the box, you get one pen and a disposable needle with four doses in it.
- 0:07As I said one for each week and now I'm not going to be able to get into it.
- 0:12It's typical isn't it? Okay so we have the spare needles and over fine plus and we
- 0:21actually, oh my god I'm shaking, and we have the the osmpic jab itself. Let's have a look.
- 0:30Yes so you can see the osmpic liquid here and this is where you put the needle.
- 0:38So you take the tab off, you can just see a little needle there and you literally push this
- 0:46in like that and you screw it up basically like you would a screwy thing, I don't know like a
- 0:56screw. You take off the outer cap and then this next one here you take that off and there is the needle,
- 1:05you can see it, it's like it's tiny. You see that? It's really small.
- 1:12So then you select 0.25 with this twisty thing here and now you're ready to inject,
- 1:21so I'm going to inject into my thigh and you basically stick it in, hold the button down,
- 1:26count to 10 and then pull it out, count to 10 slowly.
- 1:31This then clicks and takes you back to the zero once you've done that. I've just injected it,
- 1:36didn't hurt, it was really easy. It makes a really weird clicky clicky clicky clicky click noise
- 1:41and that's how you know that it's been done. So then we put the needle cap back on,
- 1:50this one here and then we put this one on and then you unscrew it and then that's ready to go in
- 1:59in the sharp spin and that's it and then I'll do that again next Wednesday.
- 2:04Wishing me luck.
Ozempic unboxing videos: what they show and what they skip
Quick answer
The creator demonstrates subcutaneous injection of semaglutide at the 0.25 mg starting dose into the thigh using an Ozempic autoinjector pen, consistent with standard titration initiation protocol. She correctly identifies the injection site and button-hold technique, though her description of click-based dose confirmation omits the essential step of visually verifying the dose counter returns to zero. The video shows disposal of the used needle in a sharps container, which aligns with UK safe disposal requirements for sharps waste.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic unboxing videos: what they show and what they skip, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic unboxing videos: what they show and what they skip" from Cheri. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator demonstrates subcutaneous injection of semaglutide at the 0.
The reason this review is not generic is the source wording and the canonical claim label "glp1 onthisday reshare of unboxing my first ozempic pen weightlos." In this clip, the useful excerpt is: "So here is the box, you get one pen and a disposable needle with four doses in it." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator demonstrates subcutaneous injection of semaglutide at the 0.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator demonstrates subcutaneous injection of semaglutide at the 0.25 mg starting dose into the thigh using an Ozempic autoinjector pen, consistent with standard titration initiation protocol. She correctly identifies the injection site and button-hold technique, though her description of click-based dose confirmation omits the essential step of visually verifying the dose counter returns to zero. The video shows disposal of the used needle in a sharps container, which aligns with UK safe disposal requirements for sharps waste.
- 0.25 mg once weekly is the correct semaglutide starting dose, used for at least 4 weeks before titration per SUSTAIN trial protocols.
- The Ozempic autoinjector pen contains 4 doses per pen, not a single-use device, which the creator correctly identifies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- 0.25 mg once weekly is the correct semaglutide starting dose, used for at least 4 weeks before titration per SUSTAIN trial protocols.
- The Ozempic autoinjector pen contains 4 doses per pen, not a single-use device, which the creator correctly identifies.
- Dose delivery confirmation requires visual verification that the dose counter reads zero, not just listening for a click, per Novo Nordisk prescribing guidance.
- The thigh is a valid injection site. Davies et al. (2021, Diabetes Care) confirmed equivalent absorption across thigh, abdomen, and upper arm.
- Ozempic holds a UK licence for type 2 diabetes, not standalone weight management. Wegovy is the licensed weight management formulation of semaglutide.
- Wilding et al. (2021, NEJM) found 14.9% mean weight reduction with semaglutide 2.4 mg over 68 weeks, achieved alongside structured lifestyle intervention, not injection technique alone.
- Used needles must be disposed of in an approved sharps container under UK regulations, a step the creator correctly demonstrates.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @chezziemai actually say?
This is a reshared unboxing of a first Ozempic pen. The creator walks through the pen components, describes screwing on a needle, selecting "0.25" as the dose, injecting into the thigh, holding the button for a count of 10, and listening for a clicking sound as confirmation the dose delivered. She notes it "didn't hurt" and says she'll repeat it "next Wednesday."
There's no medical advice being dispensed here, no weight loss claims beyond the hashtags, and no promises about outcomes. This is genuinely just someone showing what opening a prescription medication looks like for the first time. That context matters when evaluating what's accurate and what's worth correcting.
Does the science back this up?
The core injection mechanics she describes are broadly consistent with Novo Nordisk's own prescribing guidance, with one meaningful gap. Semaglutide at 0.25 mg weekly is the standard starting dose in both the SUSTAIN and STEP trial programs, used specifically to reduce gastrointestinal side effects before titrating upward.
Injecting into the thigh is one of the three approved subcutaneous sites, alongside the abdomen and upper arm. The instruction to hold the button down and count slowly is also correct. Novo Nordisk's patient instructions specify holding for at least 6 seconds after the click to ensure full dose delivery. The clicking mechanism is a dose counter, not purely a delivery confirmation, which is worth clarifying. Research published by Davies et al. (2021, Diabetes Care) confirmed that subcutaneous semaglutide delivery via autoinjector pen produces consistent pharmacokinetics across injection sites.
What did they get wrong (or right)?
She got the starting dose right. She got the injection site right. She got the needle attachment process roughly right, though her description of "screwing it up like a screw" is imprecise enough that a first-time user copying her technique could under-tighten the needle and risk a leaking or dislodged needle mid-injection.
The bigger issue is the "count to 10 and then pull it out, count to 10 slowly" instruction. The official guidance is to hold for at least 6 seconds after the dose counter returns to zero, not a full 10-count post-removal. Counting after removal serves no clinical purpose and is not in Novo Nordisk's instructions. It's a minor error but could confuse new users.
She also describes the click as confirmation the injection "has been done," which is partly right. The click indicates the dose counter has moved, but visual confirmation that the counter reads zero is the actual verification step. Users who rely only on sound could miss an incomplete dose.
What should you actually know?
Ozempic (semaglutide 1 mg/0.5 ml) pens are licensed in the UK for type 2 diabetes management. Wegovy (semaglutide 2.4 mg) is the licensed weight management formulation. These are different products with different licensed indications, dosing schedules, and pen configurations. The hashtags here say weight loss, but Ozempic's UK licence does not cover weight management as a standalone indication.
If you're starting a GLP-1 medication for the first time, watching a TikTok unboxing is not a substitute for reading the patient information leaflet or speaking with your prescriber. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction with semaglutide 2.4 mg over 68 weeks, but that was with structured lifestyle intervention, not injection technique borrowed from social media.
- Always confirm the dose counter reads zero after injection, not just listen for a click.
- Rotate injection sites between weeks to reduce lipohypertrophy risk.
- Needle disposal in a sharps bin is legally required in the UK, which she does mention correctly.
Bottom line
This video is more accurate than most GLP-1 content on TikTok. The creator is not making inflated claims, selling anything, or giving medical advice. The technique she shows is mostly correct. But "mostly correct" injection guidance, shared to 4,100 viewers who may be starting their own pens, is worth scrutinising. The specific errors around dose confirmation and needle attachment are small enough to seem pedantic until someone draws back an incomplete dose and doesn't know why.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Cheri · TikTok creator
4.1K views on this video
#onthisday reshare of unboxing my first ozempic pen #weightloss #weightlosstransformation #weightlossprogress #fyp #foryourpage #weightlossjourney #weightlossjourneyuk #lostweight #weightlosscheck #weightlossadvice #weightlossmotivation #weightlossmotivationuk
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about 0.25 mg once weekly?
0.25 mg once weekly is the correct semaglutide starting dose, used for at least 4 weeks before titration per SUSTAIN trial protocols.
What does the video say about the ozempic autoinjector pen contains 4 doses per pen, not?
The Ozempic autoinjector pen contains 4 doses per pen, not a single-use device, which the creator correctly identifies.
Dose delivery confirmation requires visual verification that the dose counter reads zero, not just listening for a click, per Novo Nordisk prescribing guidance?
Dose delivery confirmation requires visual verification that the dose counter reads zero, not just listening for a click, per Novo Nordisk prescribing guidance.
What does the video say about the thigh?
The thigh is a valid injection site. Davies et al. (2021, Diabetes Care) confirmed equivalent absorption across thigh, abdomen, and upper arm.
What does the video say about ozempic holds a uk licence for type 2 diabetes, not?
Ozempic holds a UK licence for type 2 diabetes, not standalone weight management. Wegovy is the licensed weight management formulation of semaglutide.
What does the video say about wilding et al. (2021, nejm) found 14.9% mean weight reduction?
Wilding et al. (2021, NEJM) found 14.9% mean weight reduction with semaglutide 2.4 mg over 68 weeks, achieved alongside structured lifestyle intervention, not injection technique alone.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Cheri, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.